Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Noglux (Bioksan, eda923)
- Development stage
- Unknown
- Lead developer
- Bioksan
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
Noglux is a multi-ingredient dietary supplement developed by Bioksan for the management of prediabetes and the prevention of type 2 diabetes. The formulation combines standardized white mulberry (*Morus alba*) leaf extract (Reducose®), fenugreek (*Trigonella foenum-graecum*) seed extract, inulin, *Lactiplantibacillus plantarum* A7 probiotic, niacin, zinc, and chromium. The primary active component of white mulberry leaf extract, 1-deoxynojirimycin (DNJ), acts as a competitive alpha-glucosidase inhibitor to delay carbohydrate absorption and reduce postprandial glycemic spikes. Fenugreek extract acts as an AMPK activator to improve insulin sensitivity. In clinical studies, Noglux has demonstrated significant efficacy in improving glycemic control, lipid profiles, and blood pressure, while reducing overall cardiovascular risk (SCORE2) in patients with prediabetes.
- Brand names
- Noglux
- Other names
- white mulberry leaf-based nutraceutical
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)Sucrase-Isomaltase
Beyond the preview
Go deeper on Noglux (Bioksan, eda923).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Noglux (Bioksan, eda923).